[Use of 5-butyl-1-cyclohexyl-2,4,6,-trioxoperidropyrimidine (BCP) in the prevention and therapy of neonatal hyperbilirubinemia. Comparative study with phenobarbital].
D001463:Barbiturates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D066298:In Vitro Techniques; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D010634:Phenobarbital / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D001463:Barbiturates; D010634:Phenobarbital
Impiego di 5-butil-1-cicloesil-2,4,6-trioxoperidropirimidina (BCP) nella profilassi e nella terapia dell'iperbilirubinemia neonatale. Studio comparativo con il fenobarbital